Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Pre-Tax Margin

Income before tax as a percentage of revenue.

Grifols, S.A.NASDAQ: GRFS

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin widens to 13.2%

Pre-tax margin was 13.2% in Q2 FY2026, up 3.1 pp from a year earlier. On a trailing-twelve-month basis it was 9.0%, up 0.5 pp year over year. Over 3 fiscal years it widened by 2.6 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
13.2%+6.6 pp QoQ
Last fiscal yearDec 2025
8.2%+2.0 pp YoY
LTMJun 2026
9.0%+0.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.1 pp——
1 year+2.0 pp——
3 years+2.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.2%
Year-over-year change
+2.0pp

Pre-Tax Margin vs competitors

How GRFS compares with its peers on the latest reported figures

  • GRFS's LTM Jun 2026 pre-tax margin of 9.0% is the 7th highest of the 9 companies compared; the peer median is 11.7%.
  • Its year-over-year change of +0.5 pp is the 5th highest of 9, against a peer median of -1.5 pp.
  • Over three fiscal years its change of +2.6 pp compares with a peer median of -1.2 pp.
GRFS Competitors Peer median
Pre-Tax Margin for GRFS and competitors
Company Period LTM level YoY 3-year change
ADMAADMA Biologics, Inc.LTM Jun 202642.3% +11.7 pp+78.6 pp
TECHBio-Techne CorporationLTM Sep 202618.5% +9.8 pp-10.0 pp
ABTAbbott LaboratoriesLTM Sep 202613.6% -5.0 pp+0.1 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202613.5% -4.1 pp+206.4 pp
BDXBecton, Dickinson and CompanyLTM Sep 20269.8% +1.2 pp+0.7 pp
HAEHaemonetics CorporationLTM Jun 20269.6% -6.0 pp-2.5 pp
GRFSGrifols, S.A.LTM Jun 20269.0% +0.5 pp+2.6 pp
QDELQuidelOrtho CorporationLTM Mar 2026-44.3% -32.0 pp-63.1 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-65.4% +96.3 pp-189.0 pp
Peer median (excluding GRFS) 11.7%-1.5 pp-1.2 pp

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.